METOPROLOL SUCCINATE- metoprolol succinate tablet, film coated, extended release NCS HealthCare of KY, Inc dba Vangard Labs

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use metoprolol succinate extended-release tablets safely and effectively. See full prescribing information for metoprolol succinate extended-release tablets. Metoprolol Succinate Extended-Release Tablets, USP for Oral use. "Initial U.S. Approval:1992

WARNING: ISCHEMIC HEART DISEASE

(See Full Prescribing Information for complete boxed warning)

Following abrupt cessation of therapy with beta-blocking agents, exacerbations of angina pectoris and myocardial infarction have occurred. Warn patients against interruption or discontinuation of therapy without the physician's advice. (5.1)

Metoprolol succinate extended-release tablets are indicated for the treatment of: (1)

- Metoprolol succinate extended-release tablets are indicated for the tre
- Hypertension (1.1)
- Angina Pectoris (1.2)
- Heart Failure for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.(1.3)

----- DOSAGE AND ADMINISTRATION ------

- Administer once daily. Dosing of metoprolol succinate extended-release tablets should be individualized. (2)
- Heart Failure: Recommended starting dose is 12.5 mg or 25 mg doubled every two weeks to the highest dose tolerated or up to 200 mg. (2.3)
- Hypertension: Usual initial dosage is 25 to 100 mg once daily. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. Dosages above 400 mg per day have not been studied. (2.1)
- Angina Pectoris: Usual initial dosage is 100 mg once daily. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is an unacceptable bradycardia. Dosages above 400 mg per day have not been studied. (2.2)
- Switching from immediate release metoprolol to metoprolol succinate extended-release tablets: use the same total daily dose of metoprolol succinate extended-release tablets. (2)
- ----- DOSAGE FORMS AND STRENGTHS

• Metoprolol Succinate Extended-Release Tablets:

25 mg, 50 mg, 100 mg and 200 mg. (3)

 CONTRAINDICATIONS

- Known hypersensitivity to product components. (4)
- Severe bradycardia. (4)

- -

- Heart block greater than first degree. (4)
- Cardiogenic shock. (4)
- Decompensated cardiac failure. (4)
- Sick sinus syndrome without a pacemaker. (4)

------ WARNINGS AND PRECAUTIONS ------

- Heart Failure: Worsening cardiac failure may occur. (5.2)
- Bronchospastic Disease: Avoid beta blockers. (5.3)
- Pheochromocytoma: If required, first initiate therapy with an alpha blocker. (5.4)
- Major Surgery: Avoid initiation of high-dose extended release metoprolol in patients undergoing non-cardiac surgery because it has been associated with bradycardia, hypotension, stroke and death. Do not routinely withdraw chronic beta blocker therapy prior to surgery. (5.5, 6.1)
- Diabetes and Hypoglycemia: May mask tachycardia occurring with hypoglycemia (5.6)
- Patients with Hepatic Impairment: (5.7)
- Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm (5.8)
- Anaphylactic Reactions: Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction

(5.9)

- Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency (5.10)
- Calcium Channel Blockers: Because of significant inotropic and chronotropic effects in patients treated with betablockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly (5.11).
- ADVERSE REACTIONS
 Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Wockhardt USA LLC., at 1-800-346-6854 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

- ----- DRUG INTERACTIONS
- Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents (7.1)
- CYP2D6 Inhibitors are likely to increase metoprolol concentration (7.2)
- Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia (7.3)
- Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine (7.3)

------ USE IN SPECIFIC POPULATIONS ------

- Pregnancy: There are no adequate and well-controlled studies in pregnant women. Use this drug during pregnancy only if clearly needed. (8.1)
- Nursing Mothers: Consider possible infant exposure. (8.3)
- Pediatrics: Safety and effectiveness have not been established in patients < 6 years of age. (8.4)
- Geriatrics: No notable difference in efficacy or safety vs. younger patients. (8.5)
- Hepatic Impairment: Consider initiating metoprolol succinate extended-release tablets therapy at low doses and gradually increase dosage to optimize therapy, while monitoring closely for adverse events. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2013

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE

- 1.1 Hypertension
- 1.2 Angina Pectoris
- 1.3 Heart Failure

2 DOSAGE AND ADMINISTRATION

- 2.1 Hypertension
- 2.2 Angina Pectoris
- 2.3 Heart Failure
- **3 DOSAGE FORMS AND STRENGTHS**
- **4 CONTRAINDICATIONS**

5 WARNINGS AND PRECAUTIONS

- 5.1 Ischemic Heart Disease
- 5.2 Heart Failure
- 5.3 Bronchospastic Disease
- 5.4 Pheochromocytoma
- 5.5 Major Surgery
- 5.6 Diabetes and Hypoglycemia
- 5.7 Hepatic Impairment
- 5.8 Thyrotoxicosis

5.9 Anaphylactic Reaction 5.10 Peripheral Vascular Disease 5.11 Calcium Channel Blockers **6 ADVERSE REACTIONS 6.1** Clinical Trials Experience 6.2 Post-Marketing Experience 6.3 Laboratory Test Findings **7 DRUG INTERACTIONS** 7.1 Catecholamine Depleting Drugs 7.2 CYP2D6 Inhibitors 7.3 Digitalis, Clonidine, and Calcium Channel Blockers **8 USE IN SPECIFIC POPULATIONS** 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment **10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY** 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility **14 CLINICAL STUDIES** 14.1 Angina Pectoris 14.2 Heart Failure **16. HOW SUPPLIED/STORAGE AND HANDLING 17. PATIENT COUNSELING INFORMATION**

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: ISCHEMIC HEART DISEASE:

Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered metoprolol succinate extended-release tablets, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 - 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, metoprolol succinate extended-release tablets administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Warn patients against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol succinate extended-release tablets therapy abruptly even in patients treated only for hypertension (5.1).

1 INDICATIONS AND USAGE

1.1 Hypertension

Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents [see Dosage and Administration (2)].

1.2 Angina Pectoris

Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.

1.3 Heart Failure

Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

2 DOSAGE AND ADMINISTRATION

Metoprolol succinate extended-release is an extended release tablet intended for once daily administration. For treatment of hypertension and angina, when switching from immediate release metoprolol to metoprolol succinate extended-release tablets, use the same total daily dose of metoprolol succinate extended-release tablets. Individualize the dosage of metoprolol succinate extended-release tablets. Titration may be needed in some patients.

Metoprolol succinate extended-release tablets are scored and can be divided; however, do not crush or chew the whole or half tablet.

2.1 Hypertension

Adults: The usual initial dosage is 25 to 100 mg daily in a single dose. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. Dosages above 400 mg per day have not been studied.

Pediatric Hypertensive Patients \geq 6 *Years of age*: A pediatric clinical hypertension study in patients 6 to 16 years of age did not meet its primary endpoint (dose response for reduction in SBP); however some other endpoints demonstrated effectiveness *[see Use in Specific Populations (8.4)]*. If selected for treatment, the recommended starting dose of metoprolol succinate extended-release tablet is 1.0 mg/kg once daily, but the maximum initial dose should not exceed 50 mg once daily. Dosage should be adjusted according to blood pressure response. Doses above 2.0 mg/kg (or in excess of 200 mg) once daily have not been studied in pediatric patients [see *Clinical Pharmacology (12.3)*].

Metoprolol succinate extended-release tablet is not recommended in pediatric patients < 6 years of age [see *Use in Specific Populations (8.4)*].

2.2 Angina Pectoris

Individualize the dosage of metoprolol succinate extended-release tablets. The usual initial dosage is 100 mg daily, given in a single dose. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, reduce the dosage gradually

over a period of 1 - 2 weeks [see Warnings and Precautions (5)].

2.3 Heart Failure

Dosage must be individualized and closely monitored during up-titration. Prior to initiation of metoprolol succinate extended-release tablets, stabilize the dose of other heart failure drug therapy. The recommended starting dose of metoprolol succinate extended-release tablet is 25 mg once daily for two weeks in patients with NYHA Class II heart failure and 12.5 mg once daily in patients with more severe heart failure. Double the dose every two weeks to the highest dosage level tolerated by the patient or up to 200 mg of metoprolol succinate extended-release tablets. Initial difficulty with titration should not preclude later attempts to introduce metoprolol succinate extended-release tablets. If patients experience symptomatic bradycardia, reduce the dose of metoprolol succinate extended-release doses of diuretics, lowering the dose of metoprolol succinate extended-release tablets or temporarily discontinuing it. The dose of metoprolol succinate extended-release tablets should not be increased until symptoms of worsening heart failure have been stabilized.

3 DOSAGE FORMS AND STRENGTHS

25 mg tablets: White, oval, biconvex, film-coated scored tablet debossed with "W and 34"

50 mg tablets: White, circular, beveled edge, biconvex, film-coated scored tablet debossed with "W" 735
 100 mg tablets: White, circular, beveled edge, biconvex, film-coated scored tablet debossed with "W" 736
 200 mg tablets: White, oval, beveled edge, biconvex, film-coated scored tablet debossed with "W" 737

4 CONTRAINDICATIONS

Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second or third degree heart block, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.

5 WARNINGS AND PRECAUTIONS

5.1 Is chemic Heart Disease

Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered metoprolol succinate extended-release tablets, particularly in patients with ischemic heart disease gradually reduce the dosage over a period of 1 - 2 weeks and monitor the patient. If angina markedly worsens or acute coronary ischemia develops, promptly reinstate metoprolol succinate extended-release tablets, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without their physician's advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing metoprolol succinate extended-release tablets in patients treated only for hypertension.

5.2 Heart Failure

Worsening cardiac failure may occur during up-titration of metoprolol succinate extended-release tablets. If such symptoms occur, increase diuretics and restore clinical stability before advancing the

dose of metoprolol succinate extended-release tablets [*see Dosage and Administration (2)*]. It may be necessary to lower the dose of metoprolol succinate extended-release tablets or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of metoprolol succinate extended-release tablets.

5.3 Bronchospastic Disease

PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta₁ cardio-selectivity, however, metoprolol succinate extended-release tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta₁-selectivity is not absolute, use the lowest possible dose of metoprolol succinate extended-release tablets. Bronchodilators, including beta₂-agonists, should be readily available or administered concomitantly [see Dosage and Administration (2)].

5.4 Pheochromocytoma

If metoprolol succinate extended-release tablets are used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.

5.5 Major Surgery

Avoid initiation of a high-dose regimen of extended release metoprolol in patients undergoing noncardiac surgery, since such use in patients with cardiovascular risk factors has been associated with bradycardia, hypotension, stroke and death.

Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

5.6 Diabetes and Hypoglycemia

Beta-blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected.

5.7 Hepatic Impairment

Consider initiating metoprolol succinate extended-release tablets therapy at doses lower than those recommended for a given indication; gradually increase dosage to optimize therapy, while monitoring closely for adverse events.

5.8 Thyrotoxicosis

Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may precipitate a thyroid storm.

5.9 Anaphylactic Reaction

While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat an allergic reaction.

5.10 Peripheral Vascular Disease

Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.

5.11 Calcium Channel Blockers

Because of significant inotropic and chronotropic effects in patients treated with beta-blockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly.

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in labeling:

- Worsening angina or myocardial infarction. [see Warnings and Precautions (5)]
- Worsening heart failure. [see Warnings and Precautions (5)]
- Worsening AV block. [see Contraindications (4)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Most adverse reactions have been mild and transient. The most common (>2%) adverse reactions are tiredness, dizziness, depression, diarrhea, shortness of breath, bradycardia, and rash.

Heart Failure: In the MERIT-HF study comparing metoprolol succinate extended-release tablets in daily doses up to 200 mg (mean dose 159 mg once-daily; n=1990) to placebo (n=2001), 10.3% of metoprolol succinate extended-release tablets patients discontinued for adverse reactions vs. 12.2% of placebo patients.

The table below lists adverse reactions in the MERIT-HF study that occurred at an incidence of \geq 1% in the metoprolol succinate extended-release tablets group and greater than placebo by more than 0.5%, regardless of the assessment of causality.

Adverse Reactions Occurring in the MERIT-HF Study at an Incidence ≥ 1 % in the Metoprolol Succinate Extended-Release Tablets Group and Greater Than Placebo by More Than 0.5 %

	Metoprolol succinate extended-release tablets n=1990% of patients	Placebo n=2001% of patients
Dizziness/vertigo	1.8	1.0
Bradycardia	1.5	0.4
Accident and/or injury	1.4	0.8

Post-operative Adverse Events: In a randomized, double-blind, placebo-controlled trial of 8351 patients with or at risk for atherosclerotic disease undergoing non-vascular surgery and who were not taking beta-blocker therapy, metoprolol succinate extended-release tablets 100 mg was started 2 to 4 hours prior to surgery then continued for 30 days at 200 mg per day. Metoprolol succinate extended-release tablets use was associated with a higher incidence of bradycardia (6.6% vs. 2.4%; HR 2.74; 95% Cl 2.19,3.43), hypotension (15% vs. 9.7%; HR 1.55 95% Cl 1.37,1.74), stroke (1.0% vs 0.5%; HR 2.17; 95% Cl 1.26,3.74) and death (3.1% vs 2.3%; HR 1.33; 95% Cl 1.03, 1.74) compared to placebo.

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of metoprolol succinate

extended-release tablets or immediate-release metoprolol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: Cold extremities, arterial insufficiency (usually of the Raynaud type), palpitations, peripheral edema, syncope, chest pain and hypotension.

Respiratory: Wheezing (bronchospasm), dyspnea.

Central Nervous System: Confusion, short-term memory loss, headache, somnolence, nightmares, insomnia, anxiety/nervousness, hallucinations, paresthesia.

Gastrointestinal: Nausea, dry mouth, constipation, flatulence, heartburn, hepatitis, vomiting.

Hypersensitive Reactions: Pruritus.

Miscellaneous: Musculoskeletal pain, arthralgia, blurred vision, decreased libido, male impotence, tinnitus, reversible alopecia, agranulocytosis, dry eyes, worsening of psoriasis, Peyronie's disease, sweating, photosensitivity, taste disturbance

Potential Adverse Reactions: In addition, there are adverse reactions not listed above that have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol succinate extended-release tablets.

Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, clouded sensorium, and decreased performance on neuropsychometrics.

Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Hypersensitive Reactions: Laryngospasm, respiratory distress.

6.3 Laboratory Test Findings

Clinical laboratory findings may include elevated levels of serum transaminase, alkaline phosphatase, and lactate dehydrogenase.

7 DRUG INTERACTIONS

7.1 Catecholamine Depleting Drugs

Catecholamine-depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

7.2 CYP2D6 Inhibitors

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration. In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of

metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol.

7.3 Digitalis, Clonidine, and Calcium Channel Blockers

Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta blockers can increase the risk of bradycardia.

If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped [see WARNINGS AND PRECAUTIONS (5.11)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

Metoprolol tartrate has been shown to increase post-implantation loss and decrease neonatal survival in rats at doses up to 22 times, on a mg/m² basis, the daily dose of 200 mg in a 60-kg patient. Distribution studies in mice confirm exposure of the fetus when metoprolol tartrate is administered to the pregnant animal. These studies have revealed no evidence of impaired fertility or teratogenicity. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, use this drug during pregnancy only if clearly needed.

8.3 Nursing Mothers

Metoprolol is excreted in breast milk in very small quantities. An infant consuming 1 liter of breast milk daily would receive a dose of less than 1 mg of the drug. Consider possible infant exposure when metoprolol succinate extended-release tablet is administered to a nursing woman.

8.4 Pediatric Use

One hundred forty-four hypertensive pediatric patients aged 6 to 16 years were randomized to placebo or to one of three dose levels of metoprolol succinate extended-release tablets (0.2, 1.0 or 2.0 mg/kg once daily) and followed for 4 weeks. The study did not meet its primary endpoint (dose response for reduction in SBP). Some pre-specified secondary endpoints demonstrated effectiveness including:

- Dose-response for reduction in DBP,
- 1.0 mg/kg vs. placebo for change in SBP, and
- 2.0mg/kg vs. placebo for change in SBP and DBP.

The mean placebo corrected reductions in SBP ranged from 3 to 6 mmHg, and DBP from 1 to 5 mmHg. Mean reduction in heart rate ranged from 5 to 7 bpm but considerably greater reductions were seen in some individuals [see *Dosage and Administration (2.1)*].

No clinically relevant differences in the adverse event profile were observed for pediatric patients aged 6 to 16 years as compared with adult patients.

Safety and effectiveness of metoprolol succinate extended-release tablets have not been established in patients < 6 years of age.

8.5 Geriatric Use

Clinical studies of metoprolol succinate extended-release tablets in hypertension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience in hypertensive patients has not identified

differences in responses between elderly and younger patients.

Of the 1,990 patients with heart failure randomized to metoprolol succinate extended-release tablets in the MERIT-HF trial, 50% (990) were 65 years of age and older and 12% (238) were 75 years of age and older. There were no notable differences in efficacy or the rate of adverse reactions between older and younger patients.

In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Hepatic Impairment

No studies have been performed with metoprolol succinate extended-release tablets in patients with hepatic impairment. Because metoprolol succinate extended-release tablet is metabolized by the liver, metoprolol blood levels are likely to increase substantially with poor hepatic function. Therefore, initiate therapy at doses lower than those recommended for a given indication; and increase doses gradually in patients with impaired hepatic function.

8.7 Renal Impairment

The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. No reduction in dosage is needed in patients with chronic renal failure [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Signs and Symptoms - Overdosage of metoprolol succinate extended-release tablets may lead to severe bradycardia, hypotension, and cardiogenic shock. Clinical presentation can also include: atrioventricular block, heart failure, bronchospasm, hypoxia, impairment of consciousness/coma, nausea and vomiting.

Treatment - Consider treating the patient with intensive care. Patients with myocardial infarction or heart failure may be prone to significant hemodynamic instability. Seek consultation with a regional poison control center and a medical toxicologist as needed. Beta-blocker overdose may result in significant resistance to resuscitation with adrenergic agents, including beta-agonists. On the basis of the pharmacologic actions of metoprolol, employ the following measures.

There is very limited experience with the use of hemodialysis to remove metoprolol, however metoprolol is not highly protein bound.

Bradycardia: Administer intravenous atropine; repeat to effect. If the response is inadequate, consider intravenous isoproterenol or other positive chronotropic agents. Evaluate the need for transvenous pacemaker insertion.


Hypotension: Treat underlying bradycardia. Consider intravenous vasopressor infusion, such as dopamine or norepinephrine.

Bronchospasm: Administer a beta₂-agonist, including albuterol inhalation, or an oral theophylline derivative.

Cardiac Failure: Administer diuretics or digoxin for congestive heart failure. For cardiogenic shock, consider IV dobutamine, isoproterenol, or glucagon.

11 DESCRIPTION

Metoprolol succinate is a beta₁-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended release tablets. Metoprolol succinate extended-release tablet has been formulated to provide a controlled and predictable release of metoprolol for once-daily administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 23.75, 47.5, 95 and 190 mg of metoprolol succinate equivalent to 25, 50, 100 and 200 mg of metoprolol tartrate, USP, respectively. Its chemical name is (±)1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (salt). Its structural formula is:



Metoprolol succinate is a white to off-white, fine crystalline powder with a molecular weight of 652.8. It is freely soluble in water; soluble in methanol; sparingly soluble in alcohol; slightly soluble in isopropyl alcohol. Inactive ingredients: microcrystalline cellulose, ethyl cellulose, triethyl citrate, methacrylic acid co-polymer dispersion, talc, polyethylene glycol, hypromellose, titanium dioxide, silicified microcrystalline cellulose, croscarmellose sodium and sodium stearyl fumarate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Hypertension: The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of renin activity.

Heart Failure: The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.

12.2 Pharmacodynamics

Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4)

reduction of reflex orthostatic tachycardia.

Metoprolol is a beta₁-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta₂-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.

The relative beta₁-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta₂-mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. (2) In asthmatic patients, metoprolol reduces FEV_1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta₁-receptor blocking doses.

The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation. Using an E_{max} model, the maximum effect is a 30% reduction in exercise heart rate, which is attributed to beta₁-blockade. Beta₁-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L. The relative beta₁-selectivity of metoprolol diminishes and blockade or beta₂-adrenoceptors increases at plasma concentration above 300 nmol/L.

Although beta-adrenergic receptor blockade is useful in the treatment of angina, hypertension, and heart failure there are situations in which sympathetic stimulation is vital. In patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. In the presence of AV block, beta-blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta₂-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients.

In other studies, treatment with metoprolol succinate extended-release tablets produced an improvement in left ventricular ejection fraction. Metoprolol succinate extended-release tablet was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.

12.3 Pharmacokinetics

Adults: In man, absorption of metoprolol is rapid and complete. Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism. Metoprolol crosses the bloodbrain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.

Plasma levels achieved are highly variable after oral administration. Only a small fraction of the drug (about 12%) is bound to human serum albumin. Metoprolol is a racemic mixture of R- and S- enantiomers, and is primarily metabolized by CYP2D6. When administered orally, it exhibits stereoselective metabolism that is dependent on oxidation phenotype. Elimination is mainly by biotransformation in the liver, and the plasma half-life ranges from approximately 3 to 7 hours. Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.

Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%. The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.

Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity *[see Drug Interactions (7.2)]*.

In comparison to conventional metoprolol, the plasma metoprolol levels following administration of metoprolol succinate extended-release tablets are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation. The peak plasma levels following once-daily administration of metoprolol succinate extended-release tablet average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses. At steady state the average bioavailability of metoprolol following administration of metoprolol succinate extended-release tablets, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol. Nevertheless, over the 24-hour dosing interval, β_1 -blockade is comparable and dose-related [*see Clinical Pharmacology (12)*]. The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following metoprolol succinate extended-release tablets administration.

Pediatrics: The pharmacokinetic profile of metoprolol succinate extended-release tablet was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily. The pharmacokinetics of metoprolol were similar to those described previously in adults. Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics. Metoprolol apparent oral clearance (CL/F) increased linearly with body weight. Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have been conducted to evaluate the carcinogenic potential of metoprolol tartrate. In 2-year studies in rats at three oral dosage levels of up to 800 mg/kg/day (41 times, on a mg/m² basis, the daily dose of 200 mg for a 60-kg patient), there was no increase in the development of spontaneously occurring benign or malignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli and a slight increase in biliary hyperplasia. In a 21-month study in Swiss albino mice at three oral dosage levels of up to 750 mg/kg/day (18 times, on a mg/m² basis, the daily dose of 200 mg for a 60-kg patient), benign lung tumors (small adenomas) occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total (benign plus malignant) lung tumors, nor in the overall incidence of tumors or malignant tumors. This 21-month study was repeated in CD-1 mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type of tumor.

All genotoxicity tests performed on metoprolol tartrate (a dominant lethal study in mice, chromosome studies in somatic cells, a *Salmonella*/mammalian-microsome mutagenicity test, and a nucleus anomaly test in somatic interphase nuclei) and metoprolol succinate (a *Salmonella*/mammalian-microsome mutagenicity test) were negative.

No evidence of impaired fertility due to metoprolol tartrate was observed in a study performed in rats at doses up to 22 times, on a mg/m^2 basis, the daily dose of 200 mg in a 60-kg patient.

14 CLINICAL STUDIES

In five controlled studies in normal healthy subjects, the same daily doses of metoprolol succinate extended-release tablets and immediate release metoprolol were compared in terms of the extent and duration of beta₁-blockade produced. Both formulations were given in a dose range equivalent to 100-400 mg of immediate release metoprolol per day. In these studies, metoprolol succinate extendedrelease tablet was administered once a day and immediate release metoprolol was administered once to four times a day. A sixth controlled study compared the beta₁-blocking effects of a 50 mg daily dose of the two formulations. In each study, beta₁-blockade was expressed as the percent change from baseline in exercise heart rate following standardized submaximal exercise tolerance tests at steady state. Metoprolol succinate extended-release tablets administered once a day, and immediate release metoprolol administered once to four times a day, provided comparable total beta₁-blockade over 24 hours (area under the beta₁-blockade versus time curve) in the dose range 100-400 mg. At a dosage of 50 mg once daily, metoprolol succinate extended-release tablets produced significantly higher total beta₁-blockade over 24 hours than immediate release metoprolol. For metoprolol succinate extendedrelease tablets, the percent reduction in exercise heart rate was relatively stable throughout the entire dosage interval and the level of beta₁-blockade increased with increasing doses from 50 to 300 mg daily. The effects at peak/trough (ie, at 24-hours post-dosing) were: 14/9, 16/10, 24/14, 27/22 and 27/20% reduction in exercise heart rate for doses of 50, 100, 200, 300 and 400 mg metoprolol succinate extended-release tablets once a day, respectively. In contrast to metoprolol succinate extended-release tablets, immediate release metoprolol given at a dose of 50-100 mg once a day produced a significantly larger peak effect on exercise tachycardia, but the effect was not evident at 24 hours. To match the peak to trough ratio obtained with metoprolol succinate extended-release tablets over the dosing range of 200 to 400 mg, a t.i.d. to q.i.d. divided dosing regimen was required for immediate release metoprolol. A controlled cross-over study in heart failure patients compared the plasma concentrations and beta₁-blocking effects of 50 mg immediate release metoprolol administered t.i.d., 100 mg and 200 mg metoprolol succinate extended-release tablets once daily. A 50 mg dose of immediate release metoprolol t.i.d. produced a peak plasma level of metoprolol similar to the peak level observed with 200 mg of metoprolol succinate extended-release tablets. A 200 mg dose of metoprolol succinate extended-release tablets produced a larger effect on suppression of exercise-induced and Holter-monitored heart rate over 24 hours compared to 50 mg t.i.d. of immediate release metoprolol.

In a double-blind study, 1092 patients with mild-to-moderate hypertension were randomized to once daily metoprolol succinate extended-release tablets (25, 100, or 400 mg), PLENDIL[®] (felodipine extended release tablets), the combination, or placebo. After 9 weeks, metoprolol succinate extended-release tablets alone decreased sitting blood pressure by 6-8/4-7 mmHg (placebo-corrected change from baseline) at 24 hours post-dose. The combination of metoprolol succinate extended-release tablets with PLENDIL has greater effects on blood pressure.

In controlled clinical studies, an immediate release dosage form of metoprolol was an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics at dosages of 100-450 mg daily. Metoprolol succinate extended-release tablets, in dosages of 100 to 400 mg once daily, produces similar β_1 -blockade as conventional metoprolol tablets administered two to four times daily.

In addition, metoprolol succinate extended-release tablet administered at a dose of 50 mg once daily lowered blood pressure 24-hours post-dosing in placebo-controlled studies. In controlled, comparative, clinical studies, immediate release metoprolol appeared comparable as an antihypertensive agent to propranolol, methyldopa, and thiazide-type diuretics, and affected both supine and standing blood pressure. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to drug plasma concentration, selection of proper dosage requires individual titration.

14.1 Angina Pectoris

By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris.

In controlled clinical trials, an immediate release formulation of metoprolol has been shown to be an effective antianginal agent, reducing the number of angina attacks and increasing exercise tolerance. The dosage used in these studies ranged from 100 to 400 mg daily. Metoprolol succinate extended-release tablets, in dosages of 100 to 400 mg once daily, has been shown to possess beta-blockade similar to conventional metoprolol tablets administered two to four times daily.

14.2 Heart Failure

MERIT-HF was a double-blind, placebo-controlled study of metoprolol succinate extended-release tablets conducted in 14 countries including the US. It randomized 3991 patients (1990 to metoprolol succinate extended-release tablets) with ejection fraction <0.40 and NYHA Class II-IV heart failure attributable to ischemia, hypertension, or cardiomyopathy. The protocol excluded patients with contraindications to beta-blocker use, those expected to undergo heart surgery, and those within 28 days of myocardial infarction or unstable angina. The primary endpoints of the trial were (1) all-cause mortality plus all-cause hospitalization (time to first event) and (2) all-cause mortality. Patients were stabilized on optimal concomitant therapy for heart failure, including diuretics, ACE inhibitors, cardiac glycosides, and nitrates. At randomization, 41% of patients were NYHA Class II; 55% NYHA Class III; 65% of patients had heart failure attributed to ischemic heart disease; 44% had a history of hypertension; 25% had diabetes mellitus; 48% had a history of myocardial infarction. Among patients in the trial, 90% were on diuretics, 89% were on ACE inhibitors, 64% were on digitalis, 27% were on a lipid-lowering agent, 37% were on an oral anticoagulant, and the mean ejection fraction was 0.28. The mean duration of follow-up was one year. At the end of the study, the mean daily dose of metoprolol succinate extended-release tablets was 159 mg.

The trial was terminated early for a statistically significant reduction in all-cause mortality (34%, nominal p= 0.00009). The risk of all-cause mortality plus all-cause hospitalization was reduced by 19% (p= 0.00012). The trial also showed improvements in heart failure-related mortality and heart failure-related hospitalizations, and NYHA functional class.


The table below shows the principal results for the overall study population. The figure below illustrates principal results for a wide variety of subgroup comparisons, including US vs. non-US populations (the latter of which was not pre-specified). The combined endpoints of all-cause mortality plus all-cause hospitalization and of mortality plus heart failure hospitalization showed consistent effects in the overall study population and the subgroups, including women and the US population. However, in the US subgroup (n=1071) and women (n=898), overall mortality and cardiovascular mortality appeared less affected. Analyses of female and US patients were carried out because they each represented about 25% of the overall population. Nonetheless, subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.

Clinical Endpoint	Number of Patients	Risk Reduction With Metoprolol Succinate Extended-Release Tablets	Nominal P- value
	Metoprolol Succinate Placebo Extended-Release		

Clinical Endpoints in the MERIT-HF Study

	11–2001	Tablets n=1990				
All-cause mortality plus all-caused hospitalization [*]	767	641	0.81(0.73- 0.90)	19%	0.00012	
All-cause mortality	217	145	0.66(0.53- 0.81)	34%	0.00009	
All-cause mortality plus heart failure hospitalization [*]	439	311	0.69(0.60- 0.80)	31%	0.0000008	
Cardiovascular mortality	203	128	0.62(0.50- 0.78)	38%	0.000022	
Sudden death	132	79	0.59(0.45- 0.78)	41%	0.0002	
Death due to worsening heart failure	58	30	0.51(0.33- 0.79)	49%	0.0023	
Hospitalizations due to worsening heart failure [†]	451	317	N/A	N/A	0.0000076	
Cardiovascular hospitalization [†]	773	649	N/A	N/A	0.00028	
 * Time to first event * Comparison of treatment groups examines the number of hospitalizations (Wilcoxon test); relative risk and risk reduction are not applicable. 						

Results for Subgroups in MERIT-HF



Relative risk and 95% confidence interval

US= United States; NYHA=New York Heart Association; EF= ejection fraction; MI= myocardial infarction; HR= heart rate.

16. HOW SUPPLIED/STORAGE AND HANDLING

Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, film-coated, and scored.

Tablet	Shape	Debossed	Blistercards of 30 NDC 0615-		Ι
25 mg*	Oval	W and 34	6589-39		
50 mg	Circular, beveled edge	W 735	6597-39		
		TA 7		I	Т

100 mg	Circular, beveled edge	vv 736	6598-39	
200 mg	Oval, beveled edge	W 737	7530-39	

*The 25 mg tablet is scored on both sides.

Store at 20°-25°C (68°-77°F); [see USP Controlled Room Temperature].

17. PATIENT COUNSELING INFORMATION

Advise patients to take metoprolol succinate extended-release tablets regularly and continuously, as directed, preferably with or immediately following meals. If a dose is missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue metoprolol succinate extended-release tablets without consulting the physician.

Advise patients (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with metoprolol succinate extended-release tablets has been determined; (2) to contact the physician if any difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking metoprolol succinate extended-release tablets.

Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.

PLENDIL is trademark of the AstraZeneca group of companies.

Manufactured by:

Wockhardt Limited Mumbai, India.

Distributed by:

Wockhardt USA LLC. 20 Waterview Blvd. Parsippany, NJ 07054 USA.

Rev.190312

Principal Display Panel

Metoprolol Succinate ER Tabs, USP 25mg

VLINCC OFIS-6589-39 METOPROLOL SUCCINATE ER TABS, USP 25 mg* (Software) Soft		(WOCKHARDT NDC 64 Metopr Succin ER Tabs 25 mg	olol ate
MFG BY WOCKHARDT			
PKG BY VANGARD GLASGOW, KY 42141		16	8
30	23	15	7
29	22	14	6
28	21	13	5
27	20	12	4
26	19	11	3
25	18	10	2
Omnicare 24 The overall co	1 7 nfiguration of this package is a	9 trademark of Omnicare, Inc.	1

Received: Image: Contract Leb Room température; 24 16 6 31 22 15 7 32 12 4 10 24 10 5 10 25 20 12 4 10 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 26 10 2 10 5 10			STORE AT 20) ⁰ - 25°C (68°- 77°F)
 See Package Insert Binder tor Dosage Information 20.5 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP See Package Insert Binder tor Dosage Information 50.7 mg metoprotol tartrate, USP 50 mg, torse Support 20.0 mg metoprotol 100 mg	Received:			
30 22 14 6 metoprologies succinate equivalent to 25 mg metoprologies succinate equivalent to 25 mg metoprologies succinate equivalent to 25 mg metoprologies to 2				
2 13 5 22 13 5 23 19 11 3 24 18 10 2 25 17 9 1 3 26 18 10 2 10 10 2 25 17 9 1 3 10 <td>01 10</td> <td></td> <td>metoprolol</td> <td>succinate equivalent</td>	01 10		metoprolol	succinate equivalent
		-	to 25 mg m	etoprolol tartrate, USP
	28 20 12	4		
2	27 19 11	3		
	10 10			-
Lot same Lot same Lot same Lot same Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection <				NE ODE ONET
Lot same Lot same Lot same Lot same Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection Interconnection <	METOPROLOL SUCCINATE	METOPROLOL SUCCINATE		
	LOT 6589	LOT 6589	LOT 6589	
METOPROLOL ER TAB. USP 25 mg- Lot sase METOPROLOC ER TAB	6467973403	6467973403	6467973403	6467973403
Lot 6889 Lot 6	METOPBOLOI	Pkg By Yangard, Glasgow, KY 42141 METOPBOL OI	Pig By Vangard, Glangow, KY 42141 METOPBOLOI	Pkg By Yangard, Glangow, KY 42141 METOPBOL OI
International	SUCCINATE ER TAB, USP 25 mg*			
ERT TAB. USP 25 mg- Lot ass Lot ass		6467973403		6467973403
Lot asse Lot a	METOPROLOL SUCCINATE	METOPROLOL SUCCINATE	METOPBOLOL	METOPROLOL SUCCINATE
	LOT 6589	LOT 6589	LOT 6589	LOT 6589
ER TAB. USP 25 mg- Lot asse III III IIII IIIIIIIIIIIIIIIIIIIIIIII	6467973403	6467973403	6467973403	6467973403
Lot 4889 Lot 4889 Lot 4889 Lot 4889 Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4889 Image: Lot 4	Pig By Vargard, Glasgow, KY 42141 METOPROLOL	Pkg By Yangard, Glangew, KY 42141 METICOCINIATE	Pkg By Vangard, Glasgow, KY 42141 METOCINATE	Pkg By Yangard, Glasgow, KY 42141 MELICOCINA TE
No bit to optimize to o	LOT 6589	LOT 6589	LOT 6589	LOT 6589
Lor 4387 Lor 43	6467973403	6467973403	6467973403	6467973403
Lor 4387 Lor 43	Pkg By Vangard, Glaspow, KY 42141	Pkg By Yangard, Glasgow, KY 42141	Pkg By Vangard, Glasgow, KY 42141	Pkg By Vangard, Glasgow, KY 42141
Image: State of the state o	SUCCINATE ER TAB, USP 25 mg*		SUCCINATE ER TAB, USP 25 mg*	
Augustation and a set of the set				
Imit To Produce Imit To Produce <td< td=""><td>6467973403</td><td>6467973403</td><td>6467973403</td><td>6467973403</td></td<>	6467973403	6467973403	6467973403	6467973403
LOT 6489 LOT	Pkg By Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE	Pkg By Yangard, Glasgow, KY 42141 METOPROLOL SUCCINATE	Pkg By Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE	Pkg By Yangard, Glasgow, KY 42141 METOPROLOL SUCCINATE
National Product National Product </td <td>LOT 6589</td> <td>LOT 6589</td> <td>LOT 6589</td> <td>LOT 6589</td>	LOT 6589	LOT 6589	LOT 6589	LOT 6589
ER TAB. USP 25 mg* Lot asso Lot as	6467973403	6467973403	6467973403	6467973403
ER TAB. USP 25 mg* Lot asso Lot as	Pkg By Vangard, Glatgow, EY 42141 METOPBOL OL	METOPROLOI		Pkg By Yangent, Glesgow, K7 42141
Image: Constraint Constraint Image: Constraint Constraint Image: Constraint Constraint Image: Constraint Product Constraint Product Const Product Constraint	SUCCINATE ER TAB, USP 25 mg*	SUCCINATE ER TAB, USP 25 mg*	SUCCINATE ER TAB, USP 25 mg*	ER TAB, USP 25 mg*
METOPROLOL METOPROLOL METOPROLOL METOPROLOL SUCCINATE SUCCINATE SUCCINATE SUCCINATE ERITAB, USP 25 mg* ERITAB, USP 25 mg* ERITAB, USP 25 mg* L016699 L016699 L016699				
METOPROLOL METOPROLOL METOPROLOL METOPROLOL SUCCINATE SUCCINATE SUCCINATE SUCCINATE ERITAB, USP 25 mg* ERITAB, USP 25 mg* ERITAB, USP 25 mg* L016699 L016699 L016699	Die Re Versner diesene Fit	Ole On Venned, Olevens, VV	Pla Bellannad dianan EV	Pho Re Vacanad Alamana VV d
LOT 6589 LOT 6589 LOT 6589	METOPROLOL SUCCINATE	METOPROLOL SUCCINATE	METOPROLOL SUCCINATE	METOPROLOL SUCCINATE
	LOT 6589	LOT 6589	LOT 6589	LOT 6589
	6467973403	6467973403	6467973403	6467973403

Principal Display Panel

Metoprolol Succinate


ER Tabs, USP 50mg

VLINDC OFISES WETOPROLU- SUCCINAT ER TABS, USP ST LST7 JSS4-37	N	ARDT NDC 64679-73 Aletoprolo Succinate Tabs, US 50 mg*	l	
MFG BY WOCKHAR				
PKG BY VANGARD GLASGOW, KY 4214	1		16	8
	30	23	15	7
	29	22	14	6
	28	21	13	5
	27	20	12	4
	26	19	11	3
	25	18	10	2
Omnicare	24 The overall configuration of	17 this package is a trademark of	9 Omnicare, Inc.	1

Received:		STORE AT 20 [SEE USP CONTROLLE	0°- 25°C (68°- 77°F) ED ROOM TEMPERATURE)
24 16 31 23 15 30 22 14 29 21 13 28 20 12 27 19 11 26 18 10 25 17 9 9 START DATE STAR STAR	7 6 5 4 3 2 5 5 1 S	metoprolol	
Pto By Vangend, Glasgov, 57 42141 METOP ROLOL SUCCINATE ER TAB, USP 50 mg* Lot 4597 44679735503	Pro By Vangood, Glasgov, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597 64679773603	Plg By Vangard, Slatgore, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597 4467973503	10583 Rev 00 Vangard Labe Glasgow, K7 42141
Pip Be Vangend Glasgov, 5742141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6697	Pag By Yangard Glagor, NY 43141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597	Ply By Vangard, Glasgow, KY 42141 SUCCINATE ER TAB, USP 50 mg* LOT 6597 44679773503	Pag by Yangard Glasgov, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6997
Pig transmission of state METOP RALO SUCCINATE ER TAB, USP Somg* Lot eser	Pig Printenand Glasser 27 42141 METOPROLOL SUCCINATE ER TAB, USP Somg* Lot 6597 HILL HAR USP Somg*	Pig Britager (Constant) METOPROLOL ER TAB, USP Somg* Lot 6597	Pop 97 10000 000000 07 1211 MEDOPROLO SUCCINATE ER TAB, USP 50 mg* Lot 6997 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 6467973563
Pla Berlangend Gauger, 57 (214) METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597	Ps by Yangard Biagay IV 4111 NETOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597	Ply By Vangert diagon. IV 42141 NETOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597	Pag Bryanson Glasser, Kr42141 SUCCINATE ER TAB, USP 50 mg* LOT 6597
Pro Bryanost Statut, N (2111 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597	METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597	Phy By Vanamed Generative FV 42141 SUCCINATE ER TAB, USP 50 mg* LOT 6597 MILL 64679773503	METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597
Pig Britagerd Ganger, 57 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597	Plag Bry Vacandel Glassone BY 42141 METOPROLOL SUCCINATE ER TAB, USP Somg* LOT 6597 LOT 6597	Pig Br Vacant diagon (* 4214) METOPROLOL ECCINATE ER TAB, USP 50 mg* LOT 6597	Pro By Yangard Dileston, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597
Pig Stranger Garger, 57 (214) METOPROLOLE SUCCINATE ER TAB, USP 50 mg* Lot 6597	Pig Di Vienand, Sienan, KY 42141 NETOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 64679735553	Pig Britansen Ginage FI 2111 METOPROLOL EUCINATE ER TAB, USP 50 mg* LOT 6597	Pop Br Yangend Statestr. 17 (2141 SUCCINATE ER TAB, USP 50 mg* Lot 6597 ₩₩₩₩₩₩₩₩₩₩₩₩₩ 64679735603
Pig byterste direct of definit MEDOPINGT of definit SUCCINATE ER TAB, USP 50 mg* LOT 6597	Po DY Versuel Glasger IV 40141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 4597	High Vargued Giropen (1 (211) METOPROLOL SUCCINATE ER TAB, USP 50 mg* LOT 6597 HIM CONTRACTOR	Pig Br Vinged, Glarges, Kr 42141 METOPROLOL SUCCINATE ER TAB, USP 50 mg* Lot 6597

Principal Display Panel Metoprolol Succinate

ER Tabs, USP 100mg



		STODE AT 2)°- 25°C (68°- 77°F)
Received:			ED ROOM TEMPERATURE)
24 16 31 23 15 30 22 14 29 21 13 28 20 12 27 19 11 26 16 10	7 6 5 4 3 2	metoprolol to 100 mg r	contains 95 mg succinate equivalent netoprolol tartrate, USP
25 17 9 START DATE STAR		See Package Insert Binder f OR INSTITUTION	
Pop By Yangard, Glasgov, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 	Pic By Vangard, Glasgow, FY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598	Pro By Yungard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 	10385 Rev 00 Vangard Laba Glazgow, KY 42141 6467973603
Pto By Yangard, Gleogow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* Lot 4580	Pig By Vargard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 4598	Pig By Yangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598	Pig By Yangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 4598
6467973603	6467973603	6467973603	6467973603
Phy By Yungard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 	Pig By Vengard, diason, FY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 LOT 6598 LOT 6598	Prg By Yingard Glasges, IY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* Lot 6598 4467973603	Pig By Vangard, Glasgow, EY 43141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598
Plo By Yanged, Glasgor, 37 (214) METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598	Pag Br Vargard, Glasgow, NT 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 	Plo By Yangard, Glasgos, K7 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598	Pig Bryanged, Glasgew, CY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 JAN 2000 JAN 2000 JA
Pip By Vangard, Glargor, KY 43141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 	Pla Bu Vangari d'Indone, IV 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 ####################################	Fig By Yarsed Glagsa KY 45141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598	Pig By Tangard Glagow .TV 43141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598
Plp 59 Vingent, Oliegor, KY 12141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 LOT 6598	Pla By Vergard Glasgow, KY 42111 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 MILLING STREAM STREAM STREAM 6467973603	Pro Str Vingent Olingov, KY 41141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOI 4598 LOI 4598	Ply By Sequed. Glasgew. CV 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 4598
Plo By Yangard, Glasgov, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOI 6598 	Pig By Vendard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598 HILLI HILLI HILLI HILLI 6467973603	Pro by Yangard, Glasgow, KT 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOI 6598 	Pla By Vandard, Glasgow, EY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598
Po By Yangerd, Olesgor, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* Lot 4599 Lot 469973603	Pla By Vergard, Glasgow, (Y 4211) METOPROLOL SUCCINATE ER TAB, USP 100 mg* Lot 4599 4467973603	Pro By Yangard, Olangox, KT 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* Lot 6598	Pla By Vangard, Glasgow, CY 42141 METOPROLOL SUCCINATE ER TAB, USP 100 mg* LOT 6598

Principal Display Panel Metoprolol Succinate ER Tabs, USP 200mg

VLINDC 0615-7350-39 VLINDC 0615-7350-39 SUCCINATE ER TABS, USP 200 m 60 LOT 7530 EXP 11555-39	ig* Rx Only	(WOCKHARDT NDC 64679) Metoprolo Succinate ER Tabs, U 200 mg*		24 16- 31 23 15 30 22 14- 29 21 13- 28 20 12- 27 19 11- 28 20 12- 27 19 11- 26 16 10- 25 17 9	7 6 5 4 2 1 S	SEE USP CONTROLLE * Each tablet metoproloi to 200 mg r ee Package Insert Binder fi	
30				START DATE STAR		OR INSTITUTION	IAL USE ONLY
MFG BY WOCKHARDT (NDC 64679-737-02) PKG BY VANGARD GLASGOW, KY 42141		16	8	Fkg by Yongard, Bloegow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓↓	Ptg by Vangerd, Giergow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pkg By Vangerd, Slesgow, XY 421/1 METO PROLOL SUCCINATE ER TAB, USP 200 mg* Lot 7530	11864 Rev 00 Vonger of abs Glosport, 17 20121
30	23	15	7	Pkg by Vengend, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* L01 7530	Rig by Vangard, Glorgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 6467973702	Pig by Vengerd, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pig by Vangard, Glasgow, EY 43141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 4467973702
29	22	14	6	Pkg by Vangerd, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 44679733702	Pig Ity Vangard, Glatgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pkg Hy Yongard, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 	Pig fy Vengerd, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 6467973702
28	21	13	5	Pkg by Vangerd, Glesgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LoT 7530	Rig by Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 4467973702	Pkg By Yangard, Glosgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pig by Vangard, Glasgow, KY 43141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530 ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩ 6467973702
27	20	12	4	Pkg By Vangard, Glasgow, KY 43141 METOPROLOL SUCCINATE ERTAB, USP 200 mg* LOT 7530	Pkg by Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pkg By Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* Lot 7530	Pkg by Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530
27	20	12	4	Pkg By Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Ptg by Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pkg By Yongard, Glosgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pig by Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530
26	19	11	3	Pkg By Vengord, Siespow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* L07 7530	Pkg by Vangard, Glargow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	Pkg By Yongord, Glosgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* L01 7530	Pkg by Vangord, Glasgow, KY 42141 METOPROLOL ESUCCINATE ER TAB, USP 200 mg* L07 7530
25	18	10	2	Pkg By Vangard, Glosgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg*	Address Control Contro	Pkg By Vangard, Glasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530	High Yangari, Giasgow, KY 42141 METOPROLOL SUCCINATE ER TAB, USP 200 mg* LOT 7530
Omnicare The	17 werall configuration of this package is	9 a trademark of Omnicare, Inc.	,				

I

I

METOPROLOL SUCCINATE

metoprolol succinate tablet, film coated, extended release

Product Information				
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0615-6589(NDC:	64679-734)
Route of Administration	ORAL			
· · · · · · · · · ·				
Active Ingredient/Active	Molety			
	Ingredient Name		Basis of Strength	Strengt
METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23) METOPROLOL TARTRATH				
METOPROLOL SUCCINATE (U	0	INII:GEB06NHM23) ME	ETOPROLOL TARTRATE	-
METOPROLOL SUCCINATE (U	0	UNII:GEB06NHM23) ME	0	-
METOPROLOL SUCCINATE (U Inactive Ingredients	0	INII:GEB06NHM23) ME	0	-
	0	UNII:GEB06NHM23) ME	ETOPROLOL TARTRATE	-
	NII: TH25PD4CCB) (METOPROLOL - U Ingredient Name	INII:GEB06NHM23) ME	ETOPROLOL TARTRATE	25 mg
Inactive Ingredients	NII: TH25PD4CCB) (METOPROLOL - U Ingredient Name LINE (UNII: OP1R32D61U)	INII:GEB06NHM23) ME	ETOPROLOL TARTRATE	25 mg
Inactive Ingredients CELLULOSE, MICROCRYSTAL	NII: TH25PD4CCB) (METOPROLOL - U Ingredient Name LINE (UNII: OP1R32D61U) S9VYZ4B)	UNII:GEB06NHM23) ME	ETOPROLOL TARTRATE	25 mg
Inactive Ingredients CELLULOSE, MICROCRYSTAL ETHYLCELLULOSES (UNII: 728	NII: TH25PD4CCB) (METOPROLOL - U Ingredient Name LINE (UNII: OP1R32D61U) S9 VYZ4B) 6 Q XD6 UM)	INII:GEB06NHM23) ME	ETOPROLOL TARTRATE	25 mg

TITANIUM DIO XIDE (UN	NII: 15FIX9V2J	P)					
METHACRYLIC ACID - I	ETHYL ACRY	LATE COPOLYMER (1:	1) TYPE A (U	NII: NX76LV5T8J))		
TALC (UNII: 7SEV7J4R1U	J)						
CROSCARMELLOSE SC	DDIUM (UNII:	M28OL1HH48)					
SODIUM STEARYL FUM	IARATE (UNI	I: 7CV7WJK4UI)					
SILICON DIO XIDE (UNI	I: ETJ7Z6 XBU	4)					
WATER (UNII: 059QF0K	00R)						
Product Character	istics						
Color	WHITE (whit	e)	Score	!		2 pieces	
Shape	OVAL (bico	nvex)	Size			12mm	
Flavor			Impri	nt Code		W34	
Contains							
-							
Packaging							
Packaging # Item Code	Pac	kage Description	Marketi	ing Start Date	Ma	rketing End	l Date
00		kage Description LISTER PACK	Marketi	ing Start Date	Ma	rketing End	l Date
# Item Code		-	Marketi	ing Start Date	Ma	rketing End	l Date
# Item Code		-	Marketi	ing Start Date	Ма	rketing End	l Date
# Item Code	30 in 1 B	-	Marketi	ing Start Date	Ма	rketing End	l Date
 <i>Item Code</i> NDC:0615-6589-39 Marketing Information 	30 in 1 B	LISTER PACK				-	
# Item Code 1 NDC:0615-6589-39	30 in 1 B	LISTER PACK		Marketing St 07/22/2010		rketing End Marketing I	
 # Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category 	30 in 1 B rmation Applicatio	LISTER PACK		Marketing St		-	
 # Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category 	30 in 1 B rmation Applicatio	LISTER PACK		Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B C mation Applicatio ANDA090615	DISTER PACK		Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B mation Application ANDA090615 SUCCIN	DISTER PACK	ph Citation	Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B mation Application ANDA090615 SUCCIN	DISTER PACK	ph Citation	Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B Comation Application ANDA090615 SUCCIN ablet, film co	DISTER PACK	ph Citation	Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B Comation Application ANDA090615 SUCCIN ablet, film co	DISTER PACK	ph Citation	Marketing St		-	
# Item Code 1 NDC:0615-6589-39 Marketing Infor Marketing Category ANDA	30 in 1 B Comation Application ANDA090615 SUCCIN ablet, film co	DISTER PACK	ph Citation e	Marketing St	art Date	-	End Date

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)	METOPROLOL TARTRATE	50 mg		

Inactive Ingredients			
Ingredient Name	Strength		
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
ETHYLCELLULOSES (UNII: 7Z8S9VYZ4B)			
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)			
HYPROMELLOSES (UNII: 3NXW29V3WO)			
POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)			
TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)			

MET	HACRYLIC AC	ID - ETH	YL ACRYLATE COPOLYMER (1:	1) TYPE A (UN	II: NX76LV5T8J)			
TALC (UNII: 7SEV7J4R1U)								
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)								
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)								
SILICON DIO XIDE (UNII: ETJ7Z6 XBU4)								
WAT	FER (UNII: 059Q	F0 KO0 R	R)					
Pro	duct Charac	teristi	cs					
Colo	or	WHITE ((white)		Score		2	pieces
Shaj	pe	ROUND	(Circular, beveled edge)		Size		11	mm
Flav	or				Imprint Code	Imprint Code		;735
Con	tains							
Pac	kaging							
#	Item Cod	e	Package Description	Marketin	g Start Date	M	arketing	End Date
1 N	DC:0615-6597-3	9	30 in 1 BLISTER PACK					
М	rketing In	form	ation					
	0							
	rketing Catego	-	pplication Number or Monogra	ph Citation	Marketing Start	Date	Marketi	ng End Date
AND	DA	AN	DA090615		07/22/2010			

METOPROLOL SUC	CINATE				
netoprolol succinate tablet, fi	in coated, extended release				
Product Information					
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0615-6598(NI			NDC:0615-6598(NDC:	64679-736	
Route of Administration	Route of Administration ORAL				
Active Ingredient/Active	Moiety				
	Ingredient Name		Basis of Strength	Strengt	
METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23) METOPROLOL TARTRAT					
Inactive Ingredients					
	Ingredient Name			Strength	
CELLULOSE, MICROCRYSTAL	LINE (UNII: OP1R32D61U)				
ETHYLCELLULOSES (UNII: 7Z8	S9VYZ4B)				
TRIETHYL CITRATE (UNII: 8Z96	SQXD6UM)				
HYPROMELLOSES (UNII: 3NXW	29V3WO)				
POLYETHYLENE GLYCOLS (UI	,				

TALC (UNIE: 75 EV7J4R1U) Image: Second	METHACRYLIC AC	CID - ETH	YL ACRYLATE COPOLYMER (1:	1) TYPE A (UN	II: NX76LV	5T8J)		
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI) SILICON DIO XIDE (UNII: FTJ7Z6 XBU4) WATER (UNII: 059QF0KOR) WATER (UNII: 059QF0KOR) Gala Gala	TALC (UNII: 7SEV7J4R1U)							
SH.ICON DIOXIDE (UNII: ETJ726 XBU4) Image: State of the state o	CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)							
WATER (UNIE 059QF0K00R) Product Characteristics Color WHTE (white) Score 2 pieces Shape ROUND (Circular, beveled edge) Size 12mm Flavor Imprint Code W;736 Contains Imprint Code W;736 Packaging Imprint Code W;736 # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0615-6598-39 30 in 1 BLISTER PACK Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/20 10 Marketing Start Date Marketing End Date	SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)							
Product Characteristics Score 2 pieces Color WHTE (white) Size 12mm Flavor Imprint Code W;736 Contains Imprint Code W;736 Packageing V V # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0615-6598-39 30 in 1 BLISTER PACK V V V Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA90615 07/22/2010 V V V	SILICON DIO XIDE	(UNII: ET	J7Z6XBU4)					
ColorWHTE (white)Score2 piecesShapeRUUR (Licular, beveled edge)Size12mmHaverImprint ColorImprint ColorN(36)ContainsVVVVersionVersionNetter (Size)N(Size)VersionVersionNetter (Size)N(Size)NC:0615-6598-3930 in 1 BLISTER PACKMarketing Start DateMarketing End DateMarketing CategoryApplication Number or MonogramMarketing Start DateMarketing Start DateNDAANDANU2/2010N(Size)N(Size)KETEVENEUEUEUEUEUEUEUEUEUEUEUEUEUEUEUEUEUEU	WATER (UNII: 0590	QF0KO0F	R)					
ColorWHTE (white)Score2 piecesShapeRUUR (Grouter, beveled edge)SizeImmHaverImprint ColorImprint ColorN(36)ContainsVersionNarketing ColorNarketing End DateINDC:0615-6598-3930 in 1 BLISTER PACKMarketing Start DateMarketing End DateMarketing CategoryApplication Number or MonogramMarketing Start DateMarketing End DateNDAANDANUVersionNUKETURTORUS UCCINATEVersionNuVersion								
ColorWHTE (white)Score2 piecesShapeRUUR (Grouter, beveled edge)SizeImprint ColorImprint ColorImprint ColorImprint ColorMarketing ColorW(36)Imprint ColorPackage DescriptionMarketing Start DateMarketing End DateImprint ColorSi in 1 BLISTER PACKMarketing Start DateMarketing End DateImprint ColorApplication Number or Monograph CitationMarketing Start DateMarketing End DateMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateNDAApplication Number or Monograph CitationMarketing Start DateMarketing End DateKETURTURUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU								
ShapeROUND (Circular, beveled edge)Size12mmFlavorImprint CodeW;736ContainsImprint CodeW;736Packageing#Item CodePackage DescriptionMarketing Start DateMarketing End Date1NDC:0615-6598-3930 in 1 BLISTER PACKMarketing Start DateMarketing End DateMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA09061507/2/2010VVV	Product Chara	cteristi	cs					
Flavor Imprint Code W;736 Contains W;736 Packag ing Vertical State Vertical State # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:06 15-6598-39 30 in 1 BLISTER PACK Vertical Start Date Vertical Start Date Marketing Information Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 Vertical State Sta	Color	WHITE	(white)		Score	2	2 pieces	
Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:06 15-6598-39 30 in 1 BLISTER PACK Marketing Information Number or Monograph Citation Marketing Start Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Marketing Start Date Marketing Start Date Marketing End Date NDA ANDA ANDA090615 VETOPROLOUTATE	Shape	ROUND	(Circular, beveled edge)		Size		12mm	
Marketing Category Marketing Start Date Marketing End Date Marketing Information Number or Monograph Citation Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA090615 O7/22/2010 Marketing End Date Marketing End Date	Flavor				Impri	nt Code	W;736	
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0615-6598-39 30 in 1 BLISTER PACK Image: Constant C	Contains							
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0615-6598-39 30 in 1 BLISTER PACK Image: Constant C								
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0615-6598-39 30 in 1 BLISTER PACK Image: Constant C								
1 NDC:0615-6598-39 30 in 1 BLISTER PACK Marketing Information Marketing Start Date Marketing Category Application Number or Monograph Citation ANDA ANDA090615 Marketing Start Date Marketing End Date	Packaging							
Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 07/22/2010	# Item Coo	le	Package Description	Marketin	g Start D	ate M	arketing End Da	te
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 07/22/2010 WETOPROLOL SUCCINATE Vertical Start Date Vertical Start Date	1 NDC:0615-6598-3	39	30 in 1 BLISTER PACK					
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 07/22/2010 WETOPROLOL SUCCINATE Vertical Start Date Vertical Start Date								
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 07/22/2010 WETOPROLOL SUCCINATE Vertical Start Date Vertical Start Date								
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA090615 07/22/2010 07/22/2010 WETOPROLOL SUCCINATE Vertical Start Date Vertical Start Date			- / •					
ANDA ANDA090615 07/22/2010 METOPROLOL SUCCINATE	U							
METOPROLOL SUCCINATE	Marketing Categ	gory Application Number or Monograph Citation Mar		Marketii	farketing Start Date Mark		Date	
	ANDA	AN	DA090615		07/22/2010			
metoprolol succinate tablet, film coated, extended release	METOPROL	OL S	UCCINATE					
	metoprolol succin	ate table	et, film coated, extended releas	se				

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0615-7530(NDC:64679-737)
Route of Administration	ORAL		

Active Ingredient/Active Moiety				
Basis of Strength	Strength			
METOPROLOL TARTRATE	200 mg			
	Basis of Strength METOPROLOL TARTRATE			

Inactive Ingredients	
Ingredient Name	Strength
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
ETHYLCELLULOSES (UNII: 7Z8S9VYZ4B)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	
HYPROMELLOSES (UNII: 3NXW29V3WO)	
POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)	
TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)	
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)	

TALC (UNII: 7SEV7J4R1	U)						
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)							
SODIUM STEARYL FUN	SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)						
SILICON DIO XIDE (UNI	II: ETJ7Z6XBU4)						
WATER (UNII: 059QF0K	.00R)						
Product Character	istics						
Color	WHITE (white)	Sc	ore		2 pieces		
Shape	OVAL (beveled edge)	Siz	ze		20 mm		
Flavor		Im	print Code		W;737		
Contains							
Packaging							
# Item Code	Package Description	Marketin	ng Start Date	Mark	ceting End Date		
1 NDC:0615-7530-39	30 in 1 BLISTER PACK						
Marketing Info	rmation						
Marketing Category	Application Number or Monogra	ipn Citation	Marketing Start	Date N	Aarketing End Date		
ANDA	ANDA090615		07/22/2010				

Labeler - NCS HealthCare of KY, Inc dba Vangard Labs (050052943)

Establishment			
Name	Address	ID/FEI	Business Operations
NCS HealthCare of KY, Inc dba Vangard Labs		050052943	RELABEL(0615-6589,0615-6597,0615-6598,0615-7530), REPACK(0615-6589,0615-6597,0615-6598,0615-7530)

Revised: 12/2013

NCS HealthCare of KY, Inc dba Vangard Labs